#181: What's going to be hot at ACC 2013; rivaroxaban STEMI study hits print as FDA delivers setback; Watchman ups quality of life vs chronic warfarin in nonvalvular AF; FDA again seeks more info on rivaroxaban in ACS

Mar 7, 2013 12:12 EST

For the week ending March 8, 2013 we discuss the following top cardiology news from heartwire:

• What's going to be hot at ACC 2013
• Rivaroxaban STEMI study hits print as FDA delivers setback: ATLAS ACS 2-TIMI 51
• Watchman ups quality of life vs chronic warfarin in nonvalvular AF: PROTECT AF
• FDA again seeks more info on rivaroxaban in ACS

And also, in brief:

• Filling gaps in guidelines: BiV pacing, ICDs get appropriate-use criteria
• Historical declines in housework contribute to obesity in women

Join us for a comprehensive review of this week's most important cardiology news.